In the original article, there was a mistake in Table 1 as published. Since publication, it has been noticed that the rows “BMI (Kg/m2)” and “LDL (mg/dl)” incorrectly contained repeated data. The corrected version of Table 1 is shown below.
TABLE 1
| Baseline | 3 months | 6 months | 12 months | 24 months | |
|---|---|---|---|---|---|
| UPCR native-kidney (Relative decrease %) | 1.2 (0.70–2.80) | 0.81 (0.8–0.93) ‒32.5 | 0.53 (0.18–0.85) ‒55.8 | 1.10 (0.16–1.35) ‒8.3 | 0.74 (0.30–1.70) ‒38.3 |
| UPCR transplant-kidney (Relative decrease %) | 1.5 (0.78–4.3) | 1.1 (0.39–1.55)* ‒26.7 | 0.59 (0.17–1.40) ‒60.7 | 0.75 (0.16–1.33) ‒50.0 | 1.27 (0.55–1.70) ‒15.3 |
| UPCR total (Relative decrease %) | 1.3 (0.72–4.23) | 0.87 (0.54–1.18)* ‒33.1 | 0.59 (0.17–0.85)* ‒54.6 | 1.10 (0.21–1.30) ‒15.4 | 0.92 (0.36–1.83) ‒29.2 |
| Creatinine (mg/dl) | 1.66 ± 0.83 | 1.89 ± 1.62 | 1.41 ± 0.53 | 1.37 ± 0.60 | 1.78 ± 0.49 |
| CKD-EPI (ml/min) | 57.14 ± 24.49 | 57.07 ± 27.71 | 62.33 ± 23.00 | 65.63 ± 25.39 | 57.40 ± 25.47 |
| Haematuria (yes %) | 9 (69.2) | 8 (61.5) | 5 (50) | 6 (75) | 5 (100) |
| BMI (kg/m2) | 27.19 ± 6.70 | 26.25 ± 6.49 | 28.95 ± 7.68 | 23.93 ± 2.06 | 23.3 ± 2.48 |
| LDL (mg/dl) | 112.73 ± 50.53 | 99.18 ± 31.74 | 91.63 ± 25.89 | 101.67 ± 39.64 | 108.40 ± 38.06 |
| HbA1c (%) | 5.89 ± 0.98 | 5.40 ± 0.30 | 6.07 ± 1.57 | 5.53 ± 0.85 | 5.22 ± 0.40 |
| Clinical adverse events (yes %) | 0 | 0 | 0 | 0 | 0 |
Change from baseline of analytical parameters.
Median values (interquartile range 25/75 within parentheses) and relative decrease percentage of urine protein to creatinine ratio (UPCR), mean values (SD) of creatinine and estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI), presence of haematuria, body mass index (BMI), low density lipoprotein (LDL), HbA1c, and clinical adverse events before and after 3-, 6-, 12-, and 24-month treatment with budesonide was started. *p < 0.05 versus baseline.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
IgA nephropathy, IgAN recurrence in transplant kidney, proteinuria reduction, TRF-budesonide, CKD progression
Citation
Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2023) Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. Transpl Int 35:11073. doi: 10.3389/ti.2022.11073
Received
22 November 2022
Accepted
07 December 2022
Published
05 January 2023
Volume
35 - 2023
Updates
Copyright
© 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Francesc Moreso, fjmoreso@vhebron.net; Maria Jose Soler, mjsoler01@gmail.com
†These authors share senior authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.